Eva Cavallin‐Ståhl

Author

Eva Cavallin‐Ståhl

Also Known As

E Cavallin-Stahl, E Cavallin-Ståhl, E. CAVALLIN‐STÅHL, E. Cavallin-Stahl, E. Cavallin-Ståhl, E. Cavallin-Stáhl, E. Cavallin-Ståhl, E. Cavallin‐Ståhl, EVA CAVALLIN‐STÅHL, Eva Cavallin-Stahl

138

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Lund University Karolinska Institutet Uppsala University Hospital Karolinska University Hospital St Olav's University Hospital

About

Eva Cavallin‐Ståhl is an author at Lund University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	40	2.5K
2	Health Sciences	8	8	247
3	Public Health	2	2	97
4	Social Sciences	1	1	12
5	Biochemistry	1	1	11

Eva Cavallin‐Ståhl

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome Jeanette Lundin, Hans Hagberg, Roland Repp, Blood	2003	389
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J. Beyer, Peter Albers, Renske Altena, Annals of Oncology	2012	320
Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program Torgrim Tandstad, Olav Dahl, Gabriella Cohn‐Cedermark, Journal of Clinical Oncology	2009	262
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II S. Krege, J. Beyer, Rainer Souchon, European Urology Germ Cell CancerGenitourinary CancerMedicineCancer ManagementEuropean Consensus Conference	2008	252
Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group Torgrim Tandstad, Rune Smaaland, Arne Solberg, Journal of Clinical Oncology	2011	230
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study Michael Pfreundschuh, Anthony D. Ho, Eva Cavallin‐Ståhl, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMaximum TumourMedicineMalignant Blood Disorder	2008	221
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis Mattias Berglund, Ulf Thunberg, Rose‐Marie Amini, Modern Pathology Hematological MalignancyLymphoid NeoplasiaAutoimmune DiseaseMedicineMalignant Blood Disorder	2005	202
Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. Olbjørn Klepp, Arne M. Olsson, Hannah Henrikson, Journal of Clinical Oncology Prognostic FactorsSurgical OncologyVascular InvasionAdjuvant ChemotherapyGynecology	1990	157
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. Nina Aass, Olbjørn Klepp, Eva Cavallin‐Ståhl, Journal of Clinical Oncology Prognostic FactorsSurgical OncologyCancer ManagementGynecologyMetronomic Chemotherapy	1991	156
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group Torgrim Tandstad, O. Ståhl, Ulf Håkansson, Annals of Oncology Clinical StageMedicineImmunodeficienciesClinical TrialsPathology	2014	154

Page 1